Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 11 to 20 of 220 total matches.
Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015 (Issue 1467)
Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting ...
The FDA has approved Akynzeo (Helsinn/Eisai), an oral
fixed-dose combination of the substance P/neurokinin
1 (NK1) receptor antagonist netupitant and the
serotonin-3 (5-HT3) receptor antagonist palonosetron,
for prevention of acute and delayed nausea and
vomiting associated with cancer chemotherapy
in adults. Akynzeo is the first product to combine
drugs from these two classes. Palonosetron (Aloxi)
is also available as a single agent for prevention of
chemotherapy-induced and postoperative nausea
and vomiting. Netupitant is the second substance
P/NK1 receptor antagonist to be...
Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia ...
Eflapegrastim-xnst ((Rolvedon) [Spectrum]; previously
called Rolontis), a granulocyte colony-stimulating
factor (G-CSF) conjugated to an Fc fragment of human
IgG4, has been approved by the FDA to decrease
the incidence of infection, as manifested by febrile
neutropenia, in adults with nonmyeloid malignancies
receiving myelosuppressive chemotherapy that can
cause clinically significant febrile neutropenia.
Med Lett Drugs Ther. 2023 May 29;65(1677):83-4 doi:10.58347/tml.2023.1677b | Show Introduction Hide Introduction
Dolasetron for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • May 08, 1998 (Issue 1026)
Dolasetron for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy ...
Dolasetron (Anzemet - Hoechst Marion Roussel), a selective serotonin (5-HT3) receptor antagonist similar to ondansetron (Zofran) and granisetron (Kytril - Medical Letter, 36:61, 1994) is now available for both oral and intravenous use in prevention of nausea and vomiting due to cancer chemotherapy. A 5-HT3 antagonist plus dexamethasone (Decadron, and others) is the most effective regimen for prevention of acute vomiting caused by cancer chemotherapy. Dolasetron has also been approved by the FDA for prevention and treatment of postoperative nausea and...
Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Feb 01, 2016 (Issue 1487)
Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting ...
The FDA has approved rolapitant (Varubi – Tesaro),
an oral substance P/neurokinin 1 (NK1) receptor
antagonist, for use with other antiemetics to prevent
delayed nausea and vomiting associated with cancer
chemotherapy in adults. It is the third substance P/NK1 receptor antagonist to be approved in the US;
aprepitant (Emend) and netupitant (only available
in combination with the 5-HT3 receptor antagonist
palonosetron as Akynzeo) were approved earlier for
prevention of both acute and delayed chemotherapy-induced
nausea and vomiting.
Aprepitant (Emend) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • Aug 04, 2003 (Issue 1162)
Aprepitant (Emend) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy ...
Aprepitant (Emend - Merck), the first substance P/neurokinin 1 (NK1) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT3) receptor antagonists to prevent nausea and vomiting caused by highly emetogenic anticancer drugs such as cisplatin.
Palonosetron (Aloxi) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • Mar 29, 2004 (Issue 1179)
Palonosetron (Aloxi) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy ...
Palonosetron (Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT3) receptor antagonist to become available in the US and the first to be approved by the FDA for prevention of both acute and delayed nausea and vomiting due to moderately emetogenic cancer chemotherapy. It is also approved for prevention of acute nausea and vomiting due to highly emetogenic drugs such as cisplatin (Platinol, and others). Aprepitant (Emend), a substance P/neurokinin-1 receptor antagonist, was approved last year for use with a 5-HT3 antagonist and...
IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only)
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018 (Issue 1561)
IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only) ...
The FDA has approved Cinvanti (Heron), an IV
emulsion formulation of the substance P/neurokinin-1
(NK1) receptor antagonist aprepitant, for prevention
of acute and delayed chemotherapy-induced nausea
and vomiting (CINV) in adults. Aprepitant is also
available in oral capsule and suspension formulations
(Emend, and generics), and fosaprepitant, a prodrug of
aprepitant, is available in an IV formulation (Emend for
injection).
Tremelimumab (Imjudo) for Metastatic NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
-based chemotherapy for treatment of
metastatic non-small cell lung cancer (NSCLC) in
adults ...
The FDA has approved tremelimumab-actl (Imjudo –
AstraZeneca), a cytotoxic T-lymphocyte-associated
antigen 4 (CTLA-4) blocking antibody, for use in
combination with the programmed death-ligand 1
(PD-L1) blocking antibody durvalumab (Imfinzi)
and platinum-based chemotherapy for treatment of
metastatic non-small cell lung cancer (NSCLC) in
adults with no sensitizing epidermal growth factor
receptor (EGFR) mutations or anaplastic lymphoma
kinase (ALK) genomic tumor aberrations.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e31-2 doi:10.58347/tml.2023.1669h | Show Introduction Hide Introduction
Ryzneuta for Prevention of Febrile Neutropenia
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024 (Issue 1709)
myelosuppressive chemotherapy that can
cause clinically significant febrile neutropenia. It is
the first ...
Efbemalenograstim alfa-vuxw (Ryzneuta – Evive), a
nonpegylated granulocyte colony-stimulating factor
(G-CSF) conjugated to an Fc fragment of human
IgG2, has been approved by the FDA to decrease
the incidence of infection, as manifested by febrile
neutropenia, in adults with nonmyeloid malignancies
receiving myelosuppressive chemotherapy that can
cause clinically significant febrile neutropenia. It is
the first nonpegylated, long-acting G-CSF to become
available in the US. Two pegylated, long-acting
G-CSFs, pegfilgrastim (Neulasta, and biosimilars)
and eflapegrastim (Rolvedon), are...
Med Lett Drugs Ther. 2024 Aug 19;66(1709):134-5 doi:10.58347/tml.2024.1709d | Show Introduction Hide Introduction
Tislelizumab (Tevimbra) for Esophageal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
or metastatic esophageal squamous cell cancer in
adults who received prior systemic chemotherapy
that did ...
The FDA has approved tislelizumab (Tevimbra –
BeiGene), a programmed death receptor-1 (PD-1)
blocking antibody, for treatment of unresectable
or metastatic esophageal squamous cell cancer in
adults who received prior systemic chemotherapy
that did not include a programmed death ligand-1
(PD-L1) inhibitor.
Med Lett Drugs Ther. 2024 May 13;66(1702):e85-6 doi:10.58347/tml.2024.1702h | Show Introduction Hide Introduction